Skip to content

Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial

Photo

Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial — Trastuzumab and Nivolumab Combo Shows Encouraging Response in HER2-Positive Biliary Tract Cancer

Used in

Trastuzumab and Nivolumab Combo Shows Encouraging Response in HER2-Positive Biliary Tract Cancer en